Intellia Therapeutics, Inc.
$15.21
▼
-1.06%
2026-04-21 08:29:01
www.intelliatx.com
NGM: NTLA
Explore Intellia Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.8 B
Current Price
$15.21
52W High / Low
$28.25 / $6.8
Stock P/E
—
Book Value
$5.77
Dividend Yield
—
ROCE
-59.74%
ROE
-53.48%
Face Value
—
EPS
$-3.81
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
377
Beta
1.99
Debt / Equity
13.9
Current Ratio
5.08
Quick Ratio
5.08
Forward P/E
-4.62
Price / Sales
23.55
Enterprise Value
$1.24 B
EV / EBITDA
-2.87
EV / Revenue
18.28
Rating
Buy
Target Price
$25.29
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Rallybio Corporation | $8.29 | — | $43.48 M | — | -56.97% | -15.01% | $11.49 / $1.9 | $10.97 |
| 2. | ADC Therapeutics SA | $4.25 | — | $543.75 M | — | -42.38% | 73.43% | $4.98 / $1.13 | $-1.48 |
| 3. | Puma Biotechnology, Inc. | $7.37 | 12.05 | $374.96 M | — | 27.62% | 27.97% | $7.9 / $2.75 | $2.59 |
| 4. | Fractyl Health, Inc. | $0.58 | — | $90.33 M | — | -93.93% | -7.44% | $3.03 / $0.38 | $0.06 |
| 5. | Adial Pharmaceuticals, Inc. | $1.63 | — | $2.33 M | — | -147.82% | -1.71% | $687.5 / $1.54 | $4.75 |
| 6. | Regeneron Pharmaceuticals, Inc. | $753.59 | 17.99 | $79.36 B | 0.5% | 10.23% | 14.86% | $821.11 / $476.49 | $304.65 |
| 7. | Pharvaris N.V. | $28.97 | — | $1.86 B | — | -54.28% | -65.19% | $29.89 / $13.6 | $5.56 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 23.02 M | 13.78 M | 14.24 M | 16.63 M | 12.87 M | — |
| Operating Profit | -98.71 M | -111.48 M | -110 M | -120.81 M | -136.45 M | — |
| Net Profit | -95.79 M | -101.32 M | -101.25 M | -114.33 M | -128.9 M | — |
| EPS in Rs | -0.81 | -0.86 | -0.86 | -0.97 | -1.09 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 67.67 M | 57.88 M | 36.27 M | 52.12 M |
| Operating Profit | -440.99 M | -534.26 M | -515.29 M | -458.16 M |
| Net Profit | -412.69 M | -519.02 M | -481.19 M | -474.19 M |
| EPS in Rs | -3.49 | -4.39 | -4.07 | -4.01 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 842.13 M | 1.19 B | 1.3 B | 1.52 B |
| Total Liabilities | 170.73 M | 319.06 M | 250.81 M | 284.53 M |
| Equity | 671.39 M | 871.96 M | 1.05 B | 1.24 B |
| Current Assets | 527.71 M | 639.86 M | 998.33 M | 1.22 B |
| Current Liabilities | 103.88 M | 110.85 M | 115.21 M | 126.55 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -394.74 M | -348.88 M | -394.09 M | -333.29 M |
| Investing CF | 228.03 M | 125.57 M | -31.35 M | 160.31 M |
| Financing CF | 131.49 M | 185.75 M | 130.32 M | 582.96 M |
| Free CF | -395.87 M | -354.66 M | -408.07 M | -391.68 M |
| Capex | -1.13 M | -5.78 M | -13.98 M | -58.39 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 16.92% | 59.55% | -30.4% | — |
| Earnings Growth % | 20.49% | -7.86% | -1.48% | — |
| Profit Margin % | -609.85% | -896.77% | -1326.51% | -909.78% |
| Operating Margin % | -651.67% | -923.1% | -1420.51% | -879.04% |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -628.14% | -905.33% | -1395.77% | -864.51% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.